PAVmed Secures $45M Financing, Eliminates Convertible Debt, and Provides Positive Business Update
PAVM sits 50% above its 52-week low of $6.
Summary
PAVmed Inc. announced the completion of a $45 million financing round, including preferred stock and senior secured notes, which allowed the company to eliminate all outstanding convertible securities and strengthen its balance sheet, alongside positive operational updates for its subsidiaries.
Key Events · Financing and Capital Events · PAVM
-
Major Capital Raise Completed
PAVmed completed a $30 million Series D preferred stock offering and a $15 million senior secured note financing, significantly strengthening its balance sheet.
-
Convertible Debt Eliminated
Proceeds from the financing were used to eliminate all previously outstanding convertible securities, removing a major capital structure overhang.
-
Operational Progress Across Subsidiaries
The company provided positive updates on the relaunch of its medical device portfolio, Veris Health's strategic engagement with OSU and FDA submission plans, and Lucid Diagnostics' Q4 revenue, VA contract, and positive real-world data.
-
Q4/FY25 Financial Results Reported
Reported Q4 2025 GAAP net loss of approximately $1.8 million and non-GAAP adjusted loss of $0.9 million, with cash and cash equivalents at $1.5 million as of December 31, 2025.
Analysis · PAVM · Industrial Applications And Services
This 8-K details a critical recapitalization for PAVmed, directly addressing the "going concern" warning from its recent 10-K. The completion of a $30 million Series D preferred stock offering and a $15 million senior secured note financing, totaling $45 million, is a massive capital infusion relative to the company's market capitalization. Crucially, the proceeds were used to eliminate all previously outstanding convertible securities, removing a significant overhang that has historically pressured the stock. This move substantially extends the company's cash runway and de-risks its financial position, providing a strong positive signal for its long-term viability. Additionally, the company provided positive updates on its medical device portfolio relaunch, Veris Health's strategic partnerships and FDA submission plans, and Lucid Diagnostics' revenue growth, VA contract, and positive clinical data, all contributing to a strengthened operational outlook.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.2% of the 374 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PAVM was trading at $9.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $13M. The 52-week trading range was $6.00 to $28.44. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.